SG11201808457PA - Icos ligand variant immunomodulatory proteins and uses thereof - Google Patents
Icos ligand variant immunomodulatory proteins and uses thereofInfo
- Publication number
- SG11201808457PA SG11201808457PA SG11201808457PA SG11201808457PA SG11201808457PA SG 11201808457P A SG11201808457P A SG 11201808457PA SG 11201808457P A SG11201808457P A SG 11201808457PA SG 11201808457P A SG11201808457P A SG 11201808457PA SG 11201808457P A SG11201808457P A SG 11201808457PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- rule
- immunomodulatory proteins
- elliott
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 abstract 1
- 102100034980 ICOS ligand Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323608P | 2016-04-15 | 2016-04-15 | |
US201662394745P | 2016-09-14 | 2016-09-14 | |
US201662410842P | 2016-10-20 | 2016-10-20 | |
US201762472568P | 2017-03-16 | 2017-03-16 | |
US201762475162P | 2017-03-22 | 2017-03-22 | |
PCT/US2017/027811 WO2017181148A2 (en) | 2016-04-15 | 2017-04-14 | Icos ligand variant immunomodulatory proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808457PA true SG11201808457PA (en) | 2018-10-30 |
Family
ID=60042799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808457PA SG11201808457PA (en) | 2016-04-15 | 2017-04-14 | Icos ligand variant immunomodulatory proteins and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US10882914B2 (de) |
EP (1) | EP3442999A2 (de) |
JP (2) | JP7058609B2 (de) |
KR (3) | KR20230051602A (de) |
CN (1) | CN110088126A (de) |
AU (2) | AU2017250358B2 (de) |
BR (1) | BR112018070934A2 (de) |
CA (1) | CA3019199A1 (de) |
IL (1) | IL262365A (de) |
MA (1) | MA43551A (de) |
MX (2) | MX2018012472A (de) |
SG (1) | SG11201808457PA (de) |
WO (1) | WO2017181148A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
AU2017250358B2 (en) * | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018075978A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
JP7386083B2 (ja) | 2017-03-16 | 2023-11-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd80バリアント免疫調節タンパク質及びその使用 |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
CA3102086A1 (en) * | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Single-chain tnf receptor 2 agonist fusion proteins |
KR20200074137A (ko) | 2017-10-10 | 2020-06-24 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
CA3078517A1 (en) * | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
AU2019243448B2 (en) * | 2018-03-27 | 2024-05-02 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Guidance and navigation control proteins and method of making and using thereof |
US20210208163A1 (en) * | 2018-05-24 | 2021-07-08 | Rush University Medical Center | ICOSL for use as a Renal Therapeutic |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗tigit抗体 |
EP3914274A4 (de) * | 2019-01-24 | 2022-11-16 | University of Central Florida Research Foundation, Inc. | Zusammensetzungen und verfahren zur stimulation von natürlichen killerzellen |
SG11202111033VA (en) * | 2019-04-17 | 2021-11-29 | Alpine Immune Sciences Inc | Methods and uses of variant icos ligand (icosl) fusion proteins |
AU2021226352A1 (en) * | 2020-02-25 | 2022-09-29 | Momenta Pharmaceuticals, Inc. | Enzymes for sialylation of glycans |
EP4146683A1 (de) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April- und baff-hemmende immunmodulatorische proteine und verfahren zur verwendung davon |
WO2023147564A2 (en) * | 2022-01-28 | 2023-08-03 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
WO2023168436A1 (en) * | 2022-03-03 | 2023-09-07 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
KR20230155960A (ko) * | 2022-05-03 | 2023-11-13 | 고려대학교 산학협력단 | Icos와의 결합력이 향상된 icos-l 변이체 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
DE69233186T2 (de) | 1991-05-06 | 2004-06-03 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
EP0783573B1 (de) | 1994-09-23 | 2005-12-21 | The University of British Columbia | Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen |
DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | Us Gov Nat Inst Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
AU8828598A (en) | 1997-08-15 | 1999-03-08 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
WO2000008051A2 (en) | 1998-08-07 | 2000-02-17 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
EP2369002A1 (de) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren |
ES2290052T3 (es) | 1999-09-21 | 2008-02-16 | Genetics Institute, Llc | Moleculas gl50 y usos para las mismas. |
US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
US6723316B2 (en) | 1999-12-22 | 2004-04-20 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth |
GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
EP1320599A2 (de) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 moleküle: pd-l1 liganden und ihre verwendungen |
US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
ATE500808T1 (de) | 2001-05-11 | 2011-03-15 | Wellstat Biologics Corp | Onkolytische virustherapie |
WO2003005964A2 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
CA2468258C (en) | 2001-11-30 | 2011-10-11 | Jeffrey Schlom | Peptide agonists of prostate-specific antigen, and uses therefor |
US7235631B2 (en) * | 2002-02-07 | 2007-06-26 | Mayo Foundation For Medical Education And Research | ICOS mutants |
JP2005521398A (ja) | 2002-03-27 | 2005-07-21 | ベイラー カレッジ オブ メディスン | 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス |
US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
MXPA04012881A (es) | 2002-06-21 | 2005-07-05 | Wellstat Biologics Corp | Administracion de virus terapeuticos. |
EP1391213A1 (de) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Zusammensetzungen und Verfahren zur Behandlung von Krebs mit einem Maytansinoid-CD44-Antikörper Immunokonjugat und chemotherapeutische Mittel |
CN1820078A (zh) | 2002-09-09 | 2006-08-16 | 田纳西大学研究基金会 | 弹状病毒的重组突变体及其应用方法 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B8 (pt) | 2002-12-16 | 2023-02-28 | Genentech Inc | Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida |
EP1606411B1 (de) | 2003-03-27 | 2008-12-10 | Ottawa Health Research Institute | Mutante vesicular stomatitis viren und deren verwendungen |
US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
DK2292779T3 (en) | 2003-09-30 | 2017-02-27 | Univ Pennsylvania | ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF |
US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
WO2005049846A2 (en) | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
AU2004309347B2 (en) | 2003-12-19 | 2010-03-04 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
EP1919950A1 (de) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimierte fc-varianten |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
EP1909849B1 (de) | 2005-06-23 | 2013-08-07 | The University Of Houston | Verwendung von mutiertem herpes simplexvirus 2 für die krebstherapie |
US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
CA2659529C (en) | 2006-07-21 | 2016-11-01 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
EP2170946A2 (de) | 2007-07-13 | 2010-04-07 | The Johns Hopkins University | B7-dc-varianten |
CA2693623A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
US20090136917A1 (en) | 2007-10-25 | 2009-05-28 | Szalay Aladar A | Systems and methods for viral therapy |
CN101925612A (zh) | 2007-11-27 | 2010-12-22 | 维文蒂阿生物技术公司 | 针对癌相关的nfkbib变体的表位的抗体及其用途 |
WO2009076524A2 (en) | 2007-12-11 | 2009-06-18 | The University Of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
WO2009139921A2 (en) | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
ES2866623T3 (es) | 2008-11-24 | 2021-10-19 | Massachusetts Inst Technology | Métodos y composiciones para el suministro localizado de nanopartículas a un tumor |
WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
EP2283810A1 (de) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Oral verabreichte Bakterien als Träger zur systemischen Abgabe von Mitteln |
US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
KR101790187B1 (ko) | 2009-07-24 | 2017-10-25 | 이뮨 디자인 코포레이션 | 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터 |
AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
CN102740887B (zh) | 2009-09-30 | 2015-04-15 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
EP2531216B1 (de) | 2010-02-04 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Icos zur kritischen regulierung der expansion und funktion entzündlicher menschlicher th17-zellen |
KR20130049775A (ko) | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ctla4 단백질 및 이의 용도 |
TWI586806B (zh) | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
CN103596586A (zh) | 2011-04-08 | 2014-02-19 | 免疫设计公司 | 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法 |
WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
ES2694749T3 (es) | 2011-06-30 | 2018-12-27 | Genzyme Corporation | Inhibidores de la activación de células T |
EP2726503B1 (de) * | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen |
US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
KR102070472B1 (ko) | 2012-03-30 | 2020-01-29 | 이뮨 디자인 코포레이션 | Dc-사인을 발현하는 세포에 대해 개선된 형질도입 효능을 갖는 렌티바이러스 벡터 입자 |
RU2671465C2 (ru) | 2012-05-11 | 2018-10-31 | Медиммьюн Лимитед | Варианты ctla-4 |
ES2715673T3 (es) * | 2012-12-03 | 2019-06-05 | Bristol Myers Squibb Co | Mejora de la actividad anticancerosa de proteínas de fusión FC inmunomoduladoras |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
US20160271218A1 (en) | 2013-06-27 | 2016-09-22 | Mor Research Applications Ltd. | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
JP2017522312A (ja) | 2014-07-15 | 2017-08-10 | イミューン デザイン コーポレイション | Tlr4アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン |
PL3169341T3 (pl) | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
PT3177640T (pt) | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
KR20180004094A (ko) | 2014-11-06 | 2018-01-10 | 칠드런스 내셔널 메디컬 센터 | 암 및 자가면역 질환을 위한 면역 요법 |
EP3020816A1 (de) | 2014-11-11 | 2016-05-18 | University College Cork | Bakteriell vermittelte Gentherapie |
WO2016164428A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
AU2016303497A1 (en) | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
US20180221508A1 (en) | 2015-07-31 | 2018-08-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
EP3350206A1 (de) | 2015-09-14 | 2018-07-25 | Alpine Immune Sciences, Inc. | Abstimmbarer variante immunglobulin-superfamilie-domänen und manipulierte zelltherapie |
CN108290953B (zh) | 2015-10-02 | 2022-05-31 | 西福根有限公司 | 抗pd-1抗体和组合物 |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
AU2017250358B2 (en) * | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
WO2018075978A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
CA3078517A1 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
-
2017
- 2017-04-14 AU AU2017250358A patent/AU2017250358B2/en active Active
- 2017-04-14 BR BR112018070934-4A patent/BR112018070934A2/pt unknown
- 2017-04-14 JP JP2018554101A patent/JP7058609B2/ja active Active
- 2017-04-14 US US15/488,409 patent/US10882914B2/en active Active
- 2017-04-14 EP EP17733114.7A patent/EP3442999A2/de active Pending
- 2017-04-14 WO PCT/US2017/027811 patent/WO2017181148A2/en active Application Filing
- 2017-04-14 CA CA3019199A patent/CA3019199A1/en active Pending
- 2017-04-14 CN CN201780036984.0A patent/CN110088126A/zh active Pending
- 2017-04-14 KR KR1020237011245A patent/KR20230051602A/ko active Application Filing
- 2017-04-14 MX MX2018012472A patent/MX2018012472A/es unknown
- 2017-04-14 SG SG11201808457PA patent/SG11201808457PA/en unknown
- 2017-04-14 MA MA043551A patent/MA43551A/fr unknown
- 2017-04-14 KR KR1020237011244A patent/KR20230051601A/ko not_active Application Discontinuation
- 2017-04-14 KR KR1020187033049A patent/KR102536850B1/ko active IP Right Grant
-
2018
- 2018-10-11 MX MX2022009923A patent/MX2022009923A/es unknown
- 2018-10-14 IL IL262365A patent/IL262365A/en unknown
-
2020
- 2020-11-24 US US17/103,807 patent/US20210188995A1/en active Pending
-
2022
- 2022-01-28 JP JP2022012270A patent/JP2022064959A/ja active Pending
-
2023
- 2023-05-02 AU AU2023202718A patent/AU2023202718A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023202718A1 (en) | 2023-05-18 |
KR20190005879A (ko) | 2019-01-16 |
JP7058609B2 (ja) | 2022-04-22 |
US20210188995A1 (en) | 2021-06-24 |
KR20230051601A (ko) | 2023-04-18 |
IL262365A (en) | 2018-11-29 |
US10882914B2 (en) | 2021-01-05 |
CN110088126A (zh) | 2019-08-02 |
WO2017181148A2 (en) | 2017-10-19 |
MA43551A (fr) | 2018-11-07 |
KR20230051602A (ko) | 2023-04-18 |
EP3442999A2 (de) | 2019-02-20 |
JP2019514361A (ja) | 2019-06-06 |
WO2017181148A3 (en) | 2018-02-01 |
NZ746741A (en) | 2023-12-22 |
AU2017250358B2 (en) | 2023-06-01 |
KR102536850B1 (ko) | 2023-05-26 |
MX2022009923A (es) | 2022-09-09 |
AU2017250358A1 (en) | 2018-10-18 |
JP2022064959A (ja) | 2022-04-26 |
MX2018012472A (es) | 2019-08-12 |
BR112018070934A2 (pt) | 2019-02-26 |
CA3019199A1 (en) | 2017-10-19 |
US20170320959A1 (en) | 2017-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
SG11201808797XA (en) | T cell receptors | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201808709VA (en) | T cell receptors | |
SG11201903407XA (en) | Secretable variant immunomodulatory proteins and engineered cell therapy | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201808750PA (en) | T cell receptors | |
SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
SG11201808751SA (en) | T cell receptors | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201900200XA (en) | Tgfb antibodies, methods, and uses |